Why has PCOS been given a new name?

Dr. Elisabet Stener-Victorin has spent over two decades studying a condition that affects roughly one in eight women, shaping their health from adolescence into adulthood. For years, it was known as polycystic ovary syndrome—PCOS—a name that, while familiar, painted an incomplete and often misleading picture of a far more complex disorder. Now, after a landmark global effort, that name has changed. As of this year, the medical community is adopting the term polyendocrine metabolic ovarian syndrome, or PMOS, a shift driven by science, patient voices, and a decade-long consensus process that redefines how we understand and treat the condition.

The old name, rooted in a 20th-century misunderstanding, focused on ovarian cysts—structures that aren’t cysts at all, but immature follicles. More importantly, many diagnosed with the condition don’t even show these ovarian features. By centering the ovaries, PCOS obscured the reality: this is a lifelong, multi-system disorder involving hormonal imbalance, insulin resistance, and metabolic dysfunction. Women were often misdiagnosed, dismissed, or treated only for fertility or cosmetic symptoms, while their risks for type 2 diabetes, cardiovascular disease, and mental health conditions went unaddressed.

The shift to PMOS is the result of one of the most inclusive consensus efforts in medical history. Published in The Lancet, the decision emerged from a process spanning six continents, involving 56 patient and professional organizations, and gathering input from over 22,000 individuals—including more than 14,000 patients. Through iterative surveys and global dialogue, the name PMOS emerged as the clear choice, reflecting the three core aspects of the disease: "polyendocrine" for the multiple hormonal systems involved, "metabolic" for the lifelong risks of diabetes and heart disease, and "ovarian" to preserve recognition of reproductive impacts.

This renaming is not semantic—it’s transformative. For years, diagnosis took an average of more than two years, with up to 70% of patients initially misdiagnosed or ignored. Now, the new name signals to doctors, researchers, and patients that PMOS demands a holistic approach. General practitioners are encouraged to screen for insulin resistance, mental health, and cardiovascular markers, not just menstrual irregularities. Teenagers showing early signs—acne, weight gain, irregular periods—can now be identified earlier, with care that anticipates long-term health.

The ripple effects are already unfolding. Researchers at institutions like Karolinska Institutet are reframing studies to reflect the full scope of the disorder. Patient advocates celebrate a name that finally validates their lived experience. And clinicians see a path toward coordinated, whole-person care. This small change in letters carries a large promise: that women with PMOS will no longer be seen through a narrow lens, but supported across their entire health journey.